John T. Catlow

Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.

Barbara J. Ring, John T. Catlow, Thomas J. Lindsay et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 215 citations

Medicine, Pharmacokinetics, Pharmacology +17

Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection

John T. Catlow, Richard D. Barton, Matt Clements et al. · Journal of Chromatography B Biomedical Sciences and Applications · 1995 · 106 citations

Pharmacy, Pharmaceutical Analysis, Pharmacology +16

N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neurochemical Changes

Matthew Fell, Jeffrey M. Witkin, Julie F. Falcone et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 99 citations

Medicine, Neuroscience, Pharmacology +17

M1 and M2 Muscarinic Receptor Subtypes Regulate Antidepressant-Like Effects of the Rapidly Acting Antidepressant Scopolamine

Jeffrey M. Witkin, C. Overshiner, X. Li et al. · Journal of Pharmacology and Experimental Therapeutics · 2014 · 96 citations

Medicine, Pharmacology, Psychiatry +17

Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (–)-(1 R,4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039)

Linda M. Rorick‐Kehn, Bryan G. Johnson, Jennifer Burkey et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 93 citations

Medicine, Pharmacokinetics, Pharmacology +14